We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.19%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$426M
AUM Growth
-$8.17M
Cap. Flow
-$21.9M
Cap. Flow %
-5.15%
Top 10 Hldgs %
33.1%
Holding
137
New
22
Increased
24
Reduced
54
Closed
27

Top Buys

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$7.8M
2
BIIB icon
Biogen
BIIB
+$7.48M
3
FOLD
Amicus Therapeutics
FOLD
+$6.39M
4
CYTK icon
Cytokinetics
CYTK
+$6.32M
5
TRVI icon
Trevi Therapeutics
TRVI
+$4.98M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$10.2M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.03M
3
NICE icon
Nice
NICE
+$5.13M
4
MRUS
Merus
MRUS
+$4.48M
5
SNY icon
Sanofi
SNY
+$4.34M

Sector Composition

Rank Sector Weight
1 Healthcare 65.73%
2 Technology 17.1%
3 Consumer Discretionary 1.67%
4 Utilities 1.53%
5 Communication Services 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$37.3B
$27.2M 6.38%
1,620,990
+48,809
+3% +$788K
NVMI
2
Nova
NVMI
$13.9B
$20.9M 4.9%
75,836
-14,861
-16% -$3.02M
XBI icon
3
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
$16.6M 3.89%
+200,000
New +$16M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$2.02B
$14.7M 3.45%
1,571,564
-92,410
-6% -$1.02M
TSEM icon
5
Tower Semiconductor
TSEM
$26.5B
$11.5M 2.69%
264,722
+203,173
+330% +$7.8M
CYTK icon
6
Cytokinetics
CYTK
$10.9B
$10.8M 2.53%
326,718
+181,757
+125% +$6.32M
SNY icon
7
Sanofi
SNY
$107B
$10.6M 2.49%
219,515
-85,000
-28% -$4.34M
BIIB icon
8
Biogen
BIIB
$30.4B
$10.4M 2.44%
82,738
+60,000
+264% +$7.48M
AZN icon
9
AstraZeneca
AZN
$262B
$9.44M 2.21%
67,530
-20,000
-23% -$2.8M
LLY icon
10
Eli Lilly
LLY
$1.05T
$9M 2.11%
11,540
-150
-1% -$117K
NVDA icon
11
NVIDIA
NVDA
$4.91T
$8.61M 2.02%
54,515
+24,910
+84% +$3.13M
CLDX icon
12
Celldex Therapeutics
CLDX
$2.77B
$8.54M 2%
419,540
-88,289
-17% -$1.72M
NVO
13
Novo Nordisk
NVO
$223B
$7.29M 1.71%
105,677
-12,403
-11% -$844K
AMZN icon
14
Amazon
AMZN
$2.66T
$7.12M 1.67%
32,441
-4,166
-11% -$824K
CDTX
15
DELISTED
Cidara Therapeutics
CDTX
$6.72M 1.58%
138,001
+120,873
+706% +$2.9M
RARE icon
16
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
$6.57M 1.54%
180,600
+130,600
+261% +$4.71M
ORA icon
17
Ormat Technologies
ORA
$6.43B
$6.53M 1.53%
78,000
-6,000
-7% -$449K
MLYS icon
18
Mineralys Therapeutics
MLYS
$2.39B
$6.51M 1.53%
480,974
+15,448
+3% +$224K
FBRX icon
19
Forte Biosciences
FBRX
$1B
$6.4M 1.5%
+495,109
New +$4.26M
META icon
20
Meta Platforms (Facebook)
META
$1.64T
$6.29M 1.48%
8,526
-1,436
-14% -$887K
JNJ icon
21
Johnson & Johnson
JNJ
$609B
$6.24M 1.46%
40,831
-12,000
-23% -$1.84M
MLTX icon
22
CALL
MoonLake Immunotherapeutics
MLTX
$1.64B
$5.9M 1.38%
+125,000
New +$5.09M
MSFT icon
23
Microsoft
MSFT
$2.93T
$5.87M 1.38%
11,792
+7,200
+157% +$3.13M
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$5.68M 1.33%
+990,718
New +$6.39M
PHVS icon
25
Pharvaris
PHVS
$2.44B
$5.45M 1.28%
309,931
-73,925
-19% -$1.19M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
SCM
Schnieders Capital Management Pasadena, California $629M AUM 28.1% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
PA
Probity Advisors Dallas, Texas $631M AUM 17.4% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
WAAG
Wealth Alliance Advisory Group Wichita, Kansas $632M AUM 18.54% 1-Year Est. Return

Sphera Funds Management's Q2 2025 Portfolio in Review

As of Q2 2025, Sphera Funds Management held 137 positions worth $426M, down 1.9% from $434M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Sphera Funds Management withdrew a net $21.9M in Q2 2025, closing 27 positions and reducing 54 holdings. Its most notable exit was Nice, an estimated $5.13M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 74% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Amicus Therapeutics worth $5.68M.

  • Sphera Funds Management's largest Q2 2025 buy was Amicus Therapeutics: 990,718 shares worth $5.68M.
  • Sphera Funds Management added most to Tower Semiconductor in Q2 2025, an estimated $7.8M increase.
  • Sphera Funds Management's biggest Q2 2025 reduction was BridgeBio Pharma, cutting an estimated $10.2M.
  • Sphera Funds Management fully exited Nice in Q2 2025, selling an estimated $5.13M.
  • Sphera Funds Management's ten largest holdings make up 33% of its $426M portfolio in Q2 2025.
  • Sphera Funds Management opened 22 new positions and closed 27 in Q2 2025.
  • Sphera Funds Management's portfolio value fell 1.9% quarter-over-quarter to $426M.

Based on Sphera Funds Management's 13F filing for Q2 2025, filed 14 Aug 2025.